NASDAQ:AXSM - Axsome Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$3.35 +0.10 (+3.08 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$3.35
Today's Range$3.16 - $3.3668
52-Week Range$2.05 - $6.45
Volume74,355 shs
Average Volume311,290 shs
Market Capitalization$86.05 million
P/E Ratio-2.70
Dividend YieldN/A
Beta-0.31

About Axsome Therapeutics (NASDAQ:AXSM)

Axsome Therapeutics logoAxsome Therapeutics, Inc., a clinical stage biopharmaceutical company, is developing novel therapies for central nervous system (CNS) disorders. Its product candidate portfolio includes AXS-05, AXS-09, AXS-02, AXS-07, and AXS-06. AXS-05 is in the Phase III clinical trial in treatment resistant depression and in agitation associated with Alzheimer's disease, as well as in the Phase II clinical trial for smoking cessation. AXS-02 is also in the Phase III clinical trial in knee osteoarthritis associated with bone marrow lesions pursuant to a special protocol assessment and in chronic low back pain associated with Modic changes. AXS-07 is in Phase I clinical trial for the acute treatment of migraine. AXS-06 is also in Phase I clinical trial for the treatment of osteoarthritis and rheumatoid arthritis and for the reduction of the risk of nonsteroidal anti-inflammatory drug associated gastric ulcers. AXS-09 is a novel, oral medicine combination of esbupropion and dextromethorphan, which is in Phase I clinical trial. The company has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase II trial in smoking cessation. It has operations in the United States and Australia. The company was founded in 2012 and is based in New York, New York.

Receive AXSM News and Ratings via Email

Sign-up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AXSM
CUSIPN/A
Phone212-332-3241

Debt

Debt-to-Equity Ratio0.47
Current Ratio2.95
Quick Ratio2.95

Price-To-Earnings

Trailing P/E Ratio-2.70
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.49 per share
Price / Book6.84

Profitability

EPS (Most Recent Fiscal Year)($1.24)
Net Income$-28,940,000.00
Net MarginsN/A
Return on Equity-145.83%
Return on Assets-74.32%

Miscellaneous

Employees25
Outstanding Shares25,680,000

Axsome Therapeutics (NASDAQ:AXSM) Frequently Asked Questions

What is Axsome Therapeutics' stock symbol?

Axsome Therapeutics trades on the NASDAQ under the ticker symbol "AXSM."

How were Axsome Therapeutics' earnings last quarter?

Axsome Therapeutics (NASDAQ:AXSM) issued its quarterly earnings data on Tuesday, May, 8th. The company reported ($0.19) EPS for the quarter, topping analysts' consensus estimates of ($0.28) by $0.09. View Axsome Therapeutics' Earnings History.

When is Axsome Therapeutics' next earnings date?

Axsome Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Axsome Therapeutics.

What price target have analysts set for AXSM?

4 brokers have issued 12-month target prices for Axsome Therapeutics' stock. Their predictions range from $13.00 to $31.00. On average, they anticipate Axsome Therapeutics' share price to reach $20.00 in the next year. View Analyst Ratings for Axsome Therapeutics.

Are investors shorting Axsome Therapeutics?

Axsome Therapeutics saw a decrease in short interest in the month of April. As of April 13th, there was short interest totalling 565,161 shares, a decrease of 27.3% from the March 30th total of 777,419 shares. Based on an average daily volume of 153,840 shares, the short-interest ratio is presently 3.7 days. Currently, 3.4% of the company's stock are short sold.

Who are some of Axsome Therapeutics' key competitors?

Who are Axsome Therapeutics' key executives?

Axsome Therapeutics' management team includes the folowing people:
  • Dr. Herriot Tabuteau M.D., Founder, Chairman, CEO & Pres (Age 50)
  • Ms. Constance Ames, VP of Fin. & Treasurer (Age 32)
  • Dr. Randall E. Kaye M.D., Sr. Clinical Advisor (Age 56)
  • Mr. John Golubieski, Chief Financial Officer (Age 53)
  • Mr. Mark Jacobson M.A., VP of Operations and Sec. (Age 35)

When did Axsome Therapeutics IPO?

(AXSM) raised $52 million in an IPO on Thursday, November 19th 2015. The company issued 4,300,000 shares at $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. acted as the underwriters for the IPO and Brean Capital was co-manager.

Has Axsome Therapeutics been receiving favorable news coverage?

News coverage about AXSM stock has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm identifies positive and negative press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Axsome Therapeutics earned a news sentiment score of 0.19 on Accern's scale. They also assigned press coverage about the company an impact score of 45.52 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

Who are Axsome Therapeutics' major shareholders?

Axsome Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Sio Capital Management LLC (0.75%), JPMorgan Chase & Co. (0.71%), Sabby Management LLC (0.32%) and A.R.T. Advisors LLC (0.23%). View Institutional Ownership Trends for Axsome Therapeutics.

Which institutional investors are selling Axsome Therapeutics stock?

AXSM stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co.. View Insider Buying and Selling for Axsome Therapeutics.

Which institutional investors are buying Axsome Therapeutics stock?

AXSM stock was acquired by a variety of institutional investors in the last quarter, including Sio Capital Management LLC, Sabby Management LLC and A.R.T. Advisors LLC. View Insider Buying and Selling for Axsome Therapeutics.

How do I buy shares of Axsome Therapeutics?

Shares of AXSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Axsome Therapeutics' stock price today?

One share of AXSM stock can currently be purchased for approximately $3.35.

How big of a company is Axsome Therapeutics?

Axsome Therapeutics has a market capitalization of $86.05 million. The company earns $-28,940,000.00 in net income (profit) each year or ($1.24) on an earnings per share basis. Axsome Therapeutics employs 25 workers across the globe.

How can I contact Axsome Therapeutics?

Axsome Therapeutics' mailing address is 25 BROADWAY 9TH FLOOR, NEW YORK NY, 10004. The company can be reached via phone at 212-332-3241.


MarketBeat Community Rating for Axsome Therapeutics (AXSM)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  152 (Vote Outperform)
Underperform Votes:  129 (Vote Underperform)
Total Votes:  281
MarketBeat's community ratings are surveys of what our community members think about Axsome Therapeutics and other stocks. Vote "Outperform" if you believe AXSM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AXSM will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Axsome Therapeutics (NASDAQ:AXSM) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Axsome Therapeutics in the last 12 months. Their average twelve-month price target is $20.00, suggesting that the stock has a possible upside of 497.01%. The high price target for AXSM is $31.00 and the low price target for AXSM is $13.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $20.00$19.50$19.50$19.50
Price Target Upside: 497.01% upside245.13% upside245.13% upside242.11% upside

Axsome Therapeutics (NASDAQ:AXSM) Consensus Price Target History

Price Target History for Axsome Therapeutics (NASDAQ:AXSM)

Axsome Therapeutics (NASDAQ:AXSM) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/29/2018BTIG ResearchReiterated RatingBuy$16.00HighView Rating Details
12/1/2017Cantor FitzgeraldSet Price TargetBuy$13.00LowView Rating Details
7/26/2017Ladenburg ThalmannReiterated RatingBuy$28.00 ➝ $31.00HighView Rating Details
6/20/2017AegisReiterated RatingBuy$20.00HighView Rating Details
10/3/2016Brean CapitalInitiated CoverageBuy$20.00N/AView Rating Details
(Data available from 5/25/2016 forward)

Earnings

Axsome Therapeutics (NASDAQ:AXSM) Earnings History and Estimates Chart

Earnings by Quarter for Axsome Therapeutics (NASDAQ:AXSM)

Axsome Therapeutics (NASDAQ:AXSM) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.26 EPS

Axsome Therapeutics (NASDAQ AXSM) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2018($0.25)N/AView Earnings Details
5/8/2018Q1 2018($0.28)($0.19)ViewListenView Earnings Details
3/7/2018Q4 2017($0.32)($0.28)ViewListenView Earnings Details
11/8/2017Q3 2017($0.27)ViewN/AView Earnings Details
8/9/2017Q2 2017($0.31)($0.30)ViewN/AView Earnings Details
5/9/20173/31/2017($0.40)($0.41)ViewN/AView Earnings Details
3/7/2017Q4 2016($0.38)ViewN/AView Earnings Details
11/14/2016Q3($0.39)($0.38)ViewN/AView Earnings Details
8/9/2016Q2 2016($0.39)($0.36)ViewN/AView Earnings Details
5/11/2016Q116($0.28)($0.31)ViewN/AView Earnings Details
3/24/2016Q416($0.22)($0.12)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Axsome Therapeutics (NASDAQ:AXSM) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Axsome Therapeutics (NASDAQ AXSM) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 35.20%
Institutional Ownership Percentage: 16.43%
Insider Trading History for Axsome Therapeutics (NASDAQ:AXSM)
Institutional Ownership by Quarter for Axsome Therapeutics (NASDAQ:AXSM)

Axsome Therapeutics (NASDAQ AXSM) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/23/2015Randall KayeInsiderBuy1,000$9.03$9,030.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Axsome Therapeutics (NASDAQ AXSM) News Headlines

Source:
DateHeadline
Axsome Therapeutics (AXSM) Given Consensus Recommendation of "Buy" by BrokeragesAxsome Therapeutics (AXSM) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 14 at 3:41 AM
Axsome Therapeutics (AXSM) Announces  Earnings ResultsAxsome Therapeutics (AXSM) Announces Earnings Results
www.americanbankingnews.com - May 9 at 8:34 PM
Axsome Therapeutics (AXSM) Upgraded to "Hold" by Zacks Investment ResearchAxsome Therapeutics (AXSM) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - May 8 at 5:54 PM
Axsome Therapeutics (AXSM) CEO Herriot Tabuteau on Q1 2018 Results - Earnings Call TranscriptAxsome Therapeutics' (AXSM) CEO Herriot Tabuteau on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 8 at 4:05 PM
Is Axsome Therapeutics Inc’s (NASDAQ:AXSM) CEO Incentives Align With Yours?Is Axsome Therapeutics Inc’s (NASDAQ:AXSM) CEO Incentives Align With Yours?
finance.yahoo.com - May 8 at 4:05 PM
Axsome: 1Q Earnings SnapshotAxsome: 1Q Earnings Snapshot
finance.yahoo.com - May 8 at 9:50 AM
Axsome Therapeutics (AXSM) Upgraded at ValuEngineAxsome Therapeutics (AXSM) Upgraded at ValuEngine
www.americanbankingnews.com - May 4 at 12:20 AM
Axsome Therapeutics Announces AXS-05 Poster Presentation at the 2018 Annual Meeting of the American Psychiatric ...Axsome Therapeutics Announces AXS-05 Poster Presentation at the 2018 Annual Meeting of the American Psychiatric ...
globenewswire.com - May 3 at 9:47 AM
Axsome Therapeutics Announces AXS-05 Poster Presentation at the 2018 Annual Meeting of the American Psychiatric AssociationAxsome Therapeutics Announces AXS-05 Poster Presentation at the 2018 Annual Meeting of the American Psychiatric Association
finance.yahoo.com - May 3 at 9:47 AM
Axsome Therapeutics to Report First Quarter 2018 Financial Results on May 8, 2018Axsome Therapeutics to Report First Quarter 2018 Financial Results on May 8, 2018
finance.yahoo.com - May 1 at 9:51 AM
Axsome Therapeutics (AXSM) Set to Announce Earnings on MondayAxsome Therapeutics (AXSM) Set to Announce Earnings on Monday
www.americanbankingnews.com - April 30 at 8:54 AM
Axsome Therapeutics (AXSM) Receives "Buy" Rating from BTIG ResearchAxsome Therapeutics (AXSM) Receives "Buy" Rating from BTIG Research
www.americanbankingnews.com - April 29 at 9:17 AM
Axsome Therapeutics (AXSM) Sees Significant Decline in Short InterestAxsome Therapeutics (AXSM) Sees Significant Decline in Short Interest
www.americanbankingnews.com - April 29 at 1:16 AM
Axsomes late-stage study of AXS-05 in treatment-resistant depression to continue; shares up 13% premarketAxsome's late-stage study of AXS-05 in treatment-resistant depression to continue; shares up 13% premarket
seekingalpha.com - April 26 at 9:54 AM
Axsome Therapeutics Announces Positive Outcome of Interim Analysis of STRIDE-1 Phase 3 Trial of AXS-05 in Treatment Resistant DepressionAxsome Therapeutics Announces Positive Outcome of Interim Analysis of STRIDE-1 Phase 3 Trial of AXS-05 in Treatment Resistant Depression
finance.yahoo.com - April 26 at 9:54 AM
Axsome Therapeutics Hosts R&D Day Today with Key Opinion Leaders Focusing on AXS-05 and Unmet Needs in Depression, Alzheimer’s Disease Agitation, and Nicotine DependenceAxsome Therapeutics Hosts R&D Day Today with Key Opinion Leaders Focusing on AXS-05 and Unmet Needs in Depression, Alzheimer’s Disease Agitation, and Nicotine Dependence
finance.yahoo.com - April 24 at 9:56 AM
Axsome Therapeutics Announces First Patient Enrolled in Phase 2 Clinical Trial of AXS-05 in Smoking CessationAxsome Therapeutics Announces First Patient Enrolled in Phase 2 Clinical Trial of AXS-05 in Smoking Cessation
finance.yahoo.com - April 23 at 10:04 AM
BRIEF-Axsome Therapeutics Appoints Nick Pizzie, Cpa, Mba, As Chief Financial OfficerBRIEF-Axsome Therapeutics Appoints Nick Pizzie, Cpa, Mba, As Chief Financial Officer
www.reuters.com - April 20 at 10:13 AM
Should You Be Concerned About Axsome Therapeutics Inc’s (NASDAQ:AXSM) Investors?Should You Be Concerned About Axsome Therapeutics Inc’s (NASDAQ:AXSM) Investors?
finance.yahoo.com - April 20 at 10:13 AM
Axsome Therapeutics appoints Nick Pizzie as CFOAxsome Therapeutics appoints Nick Pizzie as CFO
seekingalpha.com - April 19 at 4:13 PM
Axsome Therapeutics Appoints Nick Pizzie, CPA, MBA, as Chief Financial OfficerAxsome Therapeutics Appoints Nick Pizzie, CPA, MBA, as Chief Financial Officer
feeds.benzinga.com - April 19 at 7:34 AM
Axsome Therapeutics (AXSM) Given Average Recommendation of "Hold" by BrokeragesAxsome Therapeutics (AXSM) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - April 19 at 3:40 AM
Axsome Therapeutics (AXSM) Presents At H. C. Wainwright Global Life Sciences Conference - SlideshowAxsome Therapeutics (AXSM) Presents At H. C. Wainwright Global Life Sciences Conference - Slideshow
seekingalpha.com - April 11 at 4:06 PM
Axsome Therapeutics (AXSM) Presents At Needham and Company 17th Annual Healthcare Conference - SlideshowAxsome Therapeutics (AXSM) Presents At Needham and Company 17th Annual Healthcare Conference - Slideshow
seekingalpha.com - March 29 at 4:01 PM
Axsome therapeutics to host R&D day focused on AXS-05 and unmet needs in depression, alzheimer’s disease agitation, and nicotine dependenceAxsome therapeutics to host R&D day focused on AXS-05 and unmet needs in depression, alzheimer’s disease agitation, and nicotine dependence
seekingalpha.com - March 27 at 10:12 AM
Axsome Therapeutics to Host R&D Day with Key Opinion Leaders Focused on AXS-05 and Unmet Needs in Depression, Alzheimer’s Disease Agitation, and Nicotine DependenceAxsome Therapeutics to Host R&D Day with Key Opinion Leaders Focused on AXS-05 and Unmet Needs in Depression, Alzheimer’s Disease Agitation, and Nicotine Dependence
finance.yahoo.com - March 27 at 10:12 AM
Axsome Therapeutics to Present at H.C. Wainwright Annual Global Life Sciences ConferenceAxsome Therapeutics to Present at H.C. Wainwright Annual Global Life Sciences Conference
finance.yahoo.com - March 26 at 10:50 AM
Axsome Therapeutics (AXSM) Upgraded to Sell by ValuEngineAxsome Therapeutics (AXSM) Upgraded to Sell by ValuEngine
www.americanbankingnews.com - March 25 at 8:45 PM
Axsome Therapeutics Inc (AXSM) Given Consensus Recommendation of "Hold" by AnalystsAxsome Therapeutics Inc (AXSM) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - March 25 at 3:30 AM
Axsome Therapeutics (AXSM) Downgraded by Zacks Investment Research to SellAxsome Therapeutics (AXSM) Downgraded by Zacks Investment Research to Sell
www.americanbankingnews.com - March 13 at 5:48 PM
Axsome Therapeutics Presents Scientific Rationale for the Development of AXS-05 at the 20th Annual Meeting of the ... - GlobeNewswire (press release)Axsome Therapeutics Presents Scientific Rationale for the Development of AXS-05 at the 20th Annual Meeting of the ... - GlobeNewswire (press release)
globenewswire.com - March 13 at 4:16 PM
Head to Head Survey: Axsome Therapeutics (AXSM) versus GW Pharmaceuticals PLC- (GWPH)Head to Head Survey: Axsome Therapeutics (AXSM) versus GW Pharmaceuticals PLC- (GWPH)
www.americanbankingnews.com - March 13 at 3:02 AM
Axsome Therapeutics Presents Scientific Rationale for the Development of AXS-05 at the 20th Annual Meeting of the American Society for Experimental NeurotherapeuticsAxsome Therapeutics Presents Scientific Rationale for the Development of AXS-05 at the 20th Annual Meeting of the American Society for Experimental Neurotherapeutics
finance.yahoo.com - March 12 at 4:01 PM
Axsome Therapeutics (AXSM) Releases  Earnings Results, Beats Estimates By $0.04 EPSAxsome Therapeutics (AXSM) Releases Earnings Results, Beats Estimates By $0.04 EPS
www.americanbankingnews.com - March 8 at 10:56 AM
Axsome Therapeutics, Inc. to Host Earnings CallAxsome Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - March 7 at 10:53 AM
Axsome Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business UpdateAxsome Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
finance.yahoo.com - March 7 at 10:53 AM
Axsome Therapeutics Inc (AXSM) Given Consensus Recommendation of "Buy" by BrokeragesAxsome Therapeutics Inc (AXSM) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - February 28 at 3:32 AM
Axsome Therapeutics Announces Primary Endpoint Met in Phase 1 Trial of Next Generation Product Candidate AXS-09 Containing Chirally Pure Esbupropion and DextromethorphanAxsome Therapeutics Announces Primary Endpoint Met in Phase 1 Trial of Next Generation Product Candidate AXS-09 Containing Chirally Pure Esbupropion and Dextromethorphan
finance.yahoo.com - February 26 at 10:12 AM
Axsome Therapeutics (AXSM) Scheduled to Post Earnings on MondayAxsome Therapeutics (AXSM) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - February 26 at 3:20 AM
Is Axsome Therapeutics Inc’s (NASDAQ:AXSM) Balance Sheet Strong Enough To Weather A Storm?Is Axsome Therapeutics Inc’s (NASDAQ:AXSM) Balance Sheet Strong Enough To Weather A Storm?
finance.yahoo.com - February 15 at 6:01 AM
Axsome Therapeutics Inc (AXSM) Receives Average Rating of "Buy" from BrokeragesAxsome Therapeutics Inc (AXSM) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - February 3 at 3:26 AM
Axsome Therapeutics Inc (AXSM) Sees Large Increase in Short InterestAxsome Therapeutics Inc (AXSM) Sees Large Increase in Short Interest
www.americanbankingnews.com - January 28 at 1:26 AM
Mid-Day Market Update: Dow Surges Over 100 Points; e.l.f. Beauty Shares DropMid-Day Market Update: Dow Surges Over 100 Points; e.l.f. Beauty Shares Drop
www.nasdaq.com - January 9 at 3:40 PM
Mid-Morning Market Update: Markets Mostly Higher; Acuity Brands Profit Misses ViewsMid-Morning Market Update: Markets Mostly Higher; Acuity Brands Profit Misses Views
www.benzinga.com - January 9 at 11:10 AM
Axsome Therapeutics Announces AXS-02 Independent Data Monitoring Committee Recommends Continuation of COAST-1 Trial and Discontinuation of CREATE-1 TrialAxsome Therapeutics Announces AXS-02 Independent Data Monitoring Committee Recommends Continuation of COAST-1 Trial and Discontinuation of CREATE-1 Trial
finance.yahoo.com - January 9 at 11:10 AM
Axsome Therapeutics Inc (AXSM) Receives Consensus Rating of "Buy" from AnalystsAxsome Therapeutics Inc (AXSM) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - January 9 at 5:38 AM
Critical Survey: Axsome Therapeutics (AXSM) versus The CompetitionCritical Survey: Axsome Therapeutics (AXSM) versus The Competition
www.americanbankingnews.com - January 2 at 11:10 PM
Axsome Therapeutics (AXSM) Upgraded to "Buy" at Zacks Investment ResearchAxsome Therapeutics (AXSM) Upgraded to "Buy" at Zacks Investment Research
www.americanbankingnews.com - January 1 at 5:20 PM
Axsome Therapeutics Target of Unusually Large Options Trading (AXSM)Axsome Therapeutics Target of Unusually Large Options Trading (AXSM)
www.americanbankingnews.com - December 31 at 2:40 AM
Axsome Therapeutics (AXSM) Downgraded to Hold at Zacks Investment ResearchAxsome Therapeutics (AXSM) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - December 29 at 7:18 PM

SEC Filings

Axsome Therapeutics (NASDAQ:AXSM) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Axsome Therapeutics (NASDAQ:AXSM) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Axsome Therapeutics (NASDAQ AXSM) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.